Market Overview

Morgan Stanley Initiates Theravance at Underweight

Morgan Stanley has initiated coverage on Theravance (NASDAQ: THRX) with an Underweight rating and $12 price target.

Posted-In: Morgan StanleyPrice Target Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (THRX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters